School of Nursing, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
School of Nursing, Shanghai University of Traditional Chinese Medicine, Shanghai, China
BMJ Open. 2023 Jan 11;13(1):e063161. doi: 10.1136/bmjopen-2022-063161.
Insulin therapy plays an irreplaceable role in glycaemic control among older adults with type 2 diabetes mellitus (T2DM) and can be administered by either multiple daily injections (MDI) of insulin or by a continuous subcutaneous insulin infusion (CSII) pump. Many clinical trials have compared the effects of CSII pumps and MDI in various diabetic populations, but there has been no systematic review and meta-analysis focusing on older adults with T2DM. This study aims to determine whether the CSII pump is associated with better glycaemic control relative to the MDI in older adults with T2DM.
PubMed, Medline, Cochrane Library, Web of Science core collection, China National Knowledge Infrastructure (CNKI), Wan Fang Database, Chinese Science and Technology Journal Database (VIP) and Chinese Biomedical Literature Database (SinoMed) will be searched from inception to December 2021. Only randomised controlled trials will be included, and the language of the selected studies will be restricted to English and Chinese. Two researchers will independently screen the studies, extract data, assess the risk of bias and evaluate the quality of evidence. Any disagreement will be resolved by consensus or by a third researcher. Data analysis and synthesis will be conducted using RevMan V.5.3. Subgroup analysis, sensitivity analysis and publication bias assessment will be performed, as necessary.
As this study will not contain personal information, ethical approval will not be required. The results of the study will be published in a peer-reviewed journal or at relevant conference.
CRD42021283729.
胰岛素治疗在老年 2 型糖尿病（T2DM）患者的血糖控制中发挥着不可替代的作用，可以通过多次皮下胰岛素注射（MDI）或连续皮下胰岛素输注（CSII）泵进行给药。许多临床试验比较了 CSII 泵和 MDI 在不同糖尿病患者人群中的效果，但没有专门针对老年 T2DM 患者的系统评价和荟萃分析。本研究旨在确定 CSII 泵相对于 MDI 是否能更好地控制老年 T2DM 患者的血糖。
我们将从建库到 2021 年 12 月检索 PubMed、Medline、Cochrane 图书馆、Web of Science 核心合集、中国知网（CNKI）、万方数据库、中文科技期刊数据库（VIP）和中国生物医学文献数据库（SinoMed）。仅纳入随机对照试验，所选研究的语言将限于英语和中文。两位研究者将独立筛选研究、提取数据、评估偏倚风险和评价证据质量。任何分歧将通过共识或第三位研究者解决。使用 RevMan V.5.3 进行数据分析和合成。必要时将进行亚组分析、敏感性分析和发表偏倚评估。
由于本研究不包含个人信息，因此不需要伦理批准。研究结果将发表在同行评议的期刊或相关会议上。
PROSPERO 注册号：CRD42021283729。
